Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor

AIMS: Filgotinib (GS‐6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn's disease. The aim of the present study was to investigate the impact of age and renal impai...

Descripción completa

Detalles Bibliográficos
Autores principales: Namour, Florence, Fagard, Liesbeth, Van der Aa, Annegret, Harrison, Pille, Xin, Yan, Tasset, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256002/
https://www.ncbi.nlm.nih.gov/pubmed/30088677
http://dx.doi.org/10.1111/bcp.13726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256002/
https://www.ncbi.nlm.nih.gov/pubmed/30088677
http://dx.doi.org/10.1111/bcp.13726

Ejemplares similares